The aim of the study was to see if oxcarbazepine can be used to treat migraine, like other antiepileptic drugs like valproate, topiramate and gabapentin.
The study randomly divided a group of 170 patients into two cohorts of 85. One cohort was treated with titrations of oxcarbaxepine rising from 150mg/day to a maximum of 1,200 mg/day after five days. Patients in the second cohort were given a placebo treatment.
During the final 28 days of the 15-week trial, the number of migraine attacks was measured in both groups.
Results showed there was no difference between the oxcarbazepine group and the placebo group.
Neurology (2008) 70:548-555